Gudrun Salamon

Dr. Gudrun Salamon

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2018
Verified
Conference Paper
Closed access
EREva-Maria Rathner
Eva-Maria Rathner
JDJulia Djamali
Julia Djamali
YTYannik Terhorst
Yannik Terhorst
BSBjörn Schuller
Björn Schuller
NCNicholas Cummins
Nicholas Cummins
HBHarald Baumeister
Harald Baumeister

21 May 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GSGudrun Salamon
Gudrun Salamon
UFUrsula Field-Werners
Ursula Field-Werners
SSSophie Strobl
Sophie Strobl
VHVinzenz Hübl
Vinzenz Hübl
ADAnja Diem
Anja Diem
Background: With approximately 500 people affected in Austria, epidermolysis bullosa (EB) is a rare genetic skin disease reducing the quality of life of those affected and their relatives. The intensive efforts of the patient organisation DEBRA Austria during the last decades have led to a unique situation of those affected and their relatives, with increased support and broader knowledge about the disease in the general population. The aim of the study is to evaluate the current situation of patients and their relatives living in Austria, with a focus on burdens and helpful practices. Results: The mixed-methods study consisted of two parts: a qualitative interview study to identify psychosocial aspects of EB in those affected and their relatives, and a subsequent online survey to further assess those aspects in a larger sample, resulting in a total of n=78 Austrian participants. The impact of EB on the quality of life of EB patients and their relatives in Austria is related to the current health status, psychological burden, mobility, visibility, financial situation as well as job prospects. Personal and social resources and external support have a significant influence on the individual situation. Conclusions: The outcome is mapped to concrete implications regarding targeted support for EB patients and their relatives on an individual level and their needs in regard to the Austrian health care system.

18 February 2024 in Journal of Health Psychology
Verified
Journal Article
Open access
GSGudrun Salamon
Gudrun Salamon
SSSophie Strobl
Sophie Strobl
UFUrsula Field-Werners
Ursula Field-Werners
TWTobias Welponer
Tobias Welponer
DMDédée F Murrell
Dédée F Murrell
ADAnja Diem
Anja Diem
Epidermolysis bullosa (EB) is a rare disease characterised by skin fragility and a wide variety of symptoms. The Quality of Life in Epidermolysis Bullosa (QOLEB) score is an English 17-item EB-specific validated measurement tool with two dimensions: functioning and emotions. The aim of this cross-sectional study was to develop and validate a culturally adapted German QOLEB. The following steps were carried out: translation, expert evaluation, back translation, linguistic and cultural adaptation, sample-based psychometric testing and evaluation. Data analysis was performed with n = 46 patients across all EB types. The reliability and internal consistency of the translated German QOLEB were excellent (α = 0.901). Regarding convergent validity, the QOLEB correlated highly with the iscorEB ( r = 0.879; p < 0.001). Structural similarity with the English original version was confirmed through exploratory factor analysis. In conclusion, the German QOLEB demonstrates internal reliability and construct validity and is suitable to assess the quality of life in German-speaking EB patients.

6 January 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GSGudrun Salamon
Gudrun Salamon
SSSophie Strobl
Sophie Strobl
MMMarie-Stephanie Matschnig
Marie-Stephanie Matschnig
ADAnja Diem
Anja Diem
Background: Epidermolysis bullosa (EB) is a serious, painful, hereditary and still incurable genetic condition. Due to blistering or wounds on the skin caused by the slightest touch, a person suffering from epidermolysis bullosa is prevented from achieving the same quality of life as a healthy person. Until now, psychosocial research has focused on the description of the problems of people living with the disease. Objectives: The aim of this paper is to provide a structured overview of potential psychosocial effects of epidermolysis bullosa on the everyday lives of people with the condition and to explore helpful aspects for coping with EB. Methods: Semi-structured interviews with persons living with EB were conducted. Analyses were based on a combination of a reflexive grounded theory approach and a structured coding guide. By means of purposive sampling across three countries, a high diversity within the sample was achieved in order to obtain a wide range of possible effects. Results: A total of 17 individuals living with EB across all EB types were interviewed, resulting in 36,315 words being analysed. Psychosocial aspects of EB comprise physical, emotional, social, and functional dimensions. Identified burdens and helpful aspects in dealing with EB are described along this structure. Conclusions: Our results highlight the broad range of possible psychosocial effects caused by epidermolysis bullosa. It is particularly important to recognise those affected as individuals with their personal needs and to avoid unnecessary strains. Furthermore, emotional support is crucial in every respect.

3 September 2025 in Special Care in Dentistry
Verified
Journal Article
Open access
SVSebastián Véliz
Sebastián Véliz
MAMaría Teresa Abeleira
María Teresa Abeleira
MSMaría Concepción Serrano
María Concepción Serrano
CCCarole Charavet
Carole Charavet
KFKirsten FitzGerald
Kirsten FitzGerald
SKSusanne Krämer
Susanne Krämer
Background: Epidermolysis bullosa (EB) is a rare genetic condition characterized by skin and mucosal fragility. The clinical phenotype is highly variable. Severe types and subtypes, such as junctional EB (JEB), kindler EB (KEB), and recessive dystrophic EB (RDEB), are considered to present a high risk of oral health problems, including malocclusions. Despite this, the literature on orthodontic treatment in patients with EB is scarce and is limited to a few case reports. Objective: To provide the users with information on the current best practices for orthodontic and dentofacial orthopedic diagnosis and treatment for patients with EB. Methods: Current information regarding orthodontic treatment in patients with EB was identified based on a systematic literature review. A panel of experts was invited to provide additional information based on their experience through an open‐ended form. Later, a Delphi study was performed over two rounds with a consensus threshold at 75%. Members of the medical team and patient representatives revised the final document. Results: The panel (n = 12) agreed on a total of 15 recommendations, divided into three categories: general information on EB and orthodontics; orthodontic diagnosis and orthodontic treatment. A fourth category on perspectives was developed based on the feedback provided by non‐dental members of the medical team ( n = 4) and patients ( n = 2). Conclusions: Orthodontic treatment guidelines for patients living with EB are presented, including general aspects of EB, orthodontic diagnosis, and orthodontic treatment.

23 January 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GSGudrun Salamon
Gudrun Salamon
SSSophie Strobl
Sophie Strobl
UFUrsula Field-Werners
Ursula Field-Werners
ADAnja Diem
Anja Diem
ASAgnes Schwieger-Briel
Agnes Schwieger-Briel
EPElena Pope
Elena Pope
In contrast to clinical diagnosis via external examination, patient-related outcome measures allow to access the patients’ internal perception. Particularly, in the case of epidermolysis bullosa (EB), a rare disease characterized by a wide variety of symptoms and individual courses of disease, it is central to integrate the patient’s perspective into diagnostic processes. The Instrument for Scoring Clinical Outcome of Research for EB (iscorEB) is an EB-specific measurement tool, combining a clinician score (iscorEB-c) and a patient questionnaire (iscorEB-p). The aim of this study is to establish the iscorEB-p as an independent patient-related outcome measure tool by exploring its psychometric properties. The following steps were performed on data collected via a multinational online cross-sectional study: sample-based psychometric testing and evaluation. Data analysis was performed with n=95 participants across all EB types. The reliability and internal consistency of the iscorEB-p was excellent (α=0.90). A principal component analysis with a varimax rotation resulted in a two-factor solution, explaining 55.6% of the total variance, with the distinct factors “everyday life functioning” and “specific EB symptoms”. Convergent validity was shown by high correlations to the SWLS (r=-0.52, p<0.001), the QOLEB (r=0.72, p<0.001) and EB-BoD (r=-0.73, p<0.001). In conclusion, the iscorEB-p is a reliable and valid instrument to assess the patient-reported view on the health status of EB patients.